Blood Res.  2020 Mar;55(1):57-61. 10.5045/br.2020.55.1.57.

Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience

Affiliations
  • 1Department of Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA. tchaunce@uw.edu
  • 2Division of Oncology, University of Washington Medicine, Seattle, WA, USA.
  • 3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • 4Division of Hematology, University of Washington Medicine, Seattle, WA, USA.
  • 5Division of Pathology, University of Washington Medicine, Seattle, WA, USA.

Abstract

BACKGROUND
Autologous stem cell transplantation (autoSCT) can extend remission of mantle cell lymphoma (MCL), but the management of subsequent relapse is challenging.
METHODS
We examined consecutive patients with MCL who underwent autoSCT at Veterans Affairs Puget Sound Health Care System between 2009 and 2017 (N=37).
RESULTS
Ten patients experienced disease progression after autoSCT and were included in this analysis. Median progression free survival after autoSCT was 1.8 years (range, 0.3-7.1) and median overall survival after progression was only 0.7 years (range, 0.1 to not reached). The 3 patients who survived more than 1 year after progression were treated with ibrutinib.
CONCLUSION
Our findings suggest that ibrutinib can achieve relatively prolonged control of MCL progressing after autoSCT.

Keyword

Mantle cell lymphoma; Autologous stem cell transplant; Real-world

MeSH Terms

Delivery of Health Care
Disease Progression
Disease-Free Survival
Humans
Lymphoma, Mantle-Cell*
Recurrence
Stem Cell Transplantation*
Stem Cells*
Veterans
Full Text Links
  • BR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error